Coenzyme Q (CoQ) is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. But six decades removed from its discovery, scientists still can’t describe exactly how and when it is made.
Dave Pagliarini, an associate professor of biochemistry, says the list of unknowns is daunting. How does it migrate around in the cell? How does it get used up and replenished? What genes and proteins are responsible for CoQ dysfunction? Why does its presence decline as people age?
Pagliarini, also director of metabolism at the Morgridge Institute for Research, and his group are dedicated to chipping away at many of these knowledge gaps in CoQ production and in understanding the role of CoQ deficiency in human disease. CoQ deficiencies are implicated in scores of diseases, including liver and lung failures, muscle weakness, deafness and many brain disorders such as Parkinson’s and cerebellar ataxia. The coenzyme is almost exclusively produced within the body and is often very difficult to replenish through nutritional supplements.
Against this backdrop, the Pagliarini lab is developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. In the past month, Pagliarini’s team has published three collaborative papers that gather multiple layers of information on cells where proteins have been manipulated.
“A fundamental challenge in biology lies in connecting the many ‘orphan’ proteins in our cells with specific biological processes, such as CoQ biosynthesis,” says Pagliarini. “Once we have a handle on their functions, a second challenge is to devise ways to manipulate the activity of these proteins, pharmacologically or otherwise, to control key biological processes and, ultimately, improve health.”
Research published in the journals Cell Systems (Dec. 13), Molecular Cell (Dec. 7) and Cell Chemical Biology (Nov. 29) all reveal new clues to coenzyme Q production and function.
In the Cell Chemical Biology paper, for example, the research team, led by Morgridge researcher Andrew Reidenbach, introduced a custom drug in their model organism, yeast, that is capable of turning the CoQ pathway on and off. This discovery provides a novel way for researchers to understand, within a living organism, how different levels of CoQ affect metabolic function.
“This system gives us a powerful new tool to study in a mechanistic way how this pathway works, and how we can manipulate it,” Pagliarini says. “We now think we can develop a rheostat-like control over the pathway, to produce different levels of coenzyme Q and see what that means for different phenotypes and health outcomes in cells.”
The Cell Systems paper—a jointly led project with UW-Madison biochemist Marv Wicken’s group—investigates an RNA-binding protein that has long been associated with mitochondria. But what role the protein actually plays has been difficult to nail down. In this work, led by recent Wickens Lab graduate Chris Lapointe and Jon Stefely from the Pagliarini Lab, and also in collaboration with Josh Coon’s group, created a new multi-omic strategy to identify the global function of this protein and its role in CoQ biosynthesis. This multi-omics approach — marrying proteomics, metabolomics and other “omics” tools to pinpoint a protein’s function — will be highly relevant moving forward as tool for determining future protein targets, he says.
Finally, the Molecular Cell paper shed light on proteases that live in mitochondria that are designed to “chew up” other proteins. These “Pac-man”-like proteins were once thought to serve merely as sort of cellular garbage cans to eliminate damaged proteins in the mitochondria. This study, led my Mike Veling, helped reveal them to be far more diverse in function. In particular, the team discovered a protease that helps an essential CoQ protein “mature” into its final form.
Pagliarini says all three papers could have a lasting impact in mitochondrial research that goes well beyond CoQ biology, giving scientists new methods of tracking down protein function. About a quarter of all proteins in mitochondria currently have no assigned function, and many of them could have a link to mitochondrial disease.
“For coenzyme Q, the more we understand the biosynthetic steps taking place, and what cellular processes turn them on and off, the greater the odds we can manipulate the system in a way that improves the body’s overall CoQ production,” Pagliarini says. “This would be a great therapeutic strategy: Instead of taking supplements, which don’t always get CoQ where it needs to be, you could turn the natural processes on to fight disease.”
This story was written by Brian Mattmiller of the Morgridge Institute for Research and was originally published on their website.